Julie A. Wolfson, MD, of the University of Alabama at Birmingham School of Medicine, discusses what clinicians need to be conscious about regarding the outcomes disparities between adolescents and young adults with acute lymphoblastic leukemia (ALL), and children with ALL.
Julie A. Wolfson, MD, of the University of Alabama at Birmingham School of Medicine, discusses what clinicians need to be conscious about regarding the outcomes disparities between adolescents and young adults with acute lymphoblastic leukemia (ALL), and children with ALL.
Transcript
In what ways can clinicians be conscious of the outcomes disparities between adolescents and young adults with ALL, and children with ALL?
That’s a really good question. There’s a lot of things that impact this. This is just the tip of the iceberg. We’re going to move forward and really try to figure this out but I think the first thing that clinicians can do is just to be aware that these patients are different from children and they’re different from patients that are over 40 as well. They’re different from their older adults that walk through the door and that really there’s a lot of different things that need to be considered in terms of treatment on a clinical trial and consideration of what kind of treatment they give them.
So really what I think in terms of thinking about these patients, the most important thing is for clinicians to recognize that they’re different from their younger counterparts and from their older counterparts. So when someone walks through your door and and they’re diagnosed with ALL and they’re under 40, I think the most important thing is to think about them as a unique group. Think about the kind of treatment they receive, and really, because of this duration of treatment, think about the kind of treatment you’re giving, and really, keeping them on track and making sure that they finish and don’t fall off at the end, which happens. These patients, sometimes because of all of the psycho-social stressors in their lives, they’re at this very unique time in their lives and there’s so much going on and so they do need psycho-social support in different ways. We haven’t shown this specifically and we really need to take that all into account, though.
Dr Kathy Zackowski Discusses the Importance of Rehabilitation Research and Trials in MS
April 26th 2024Kathy Zackowski, PhD, National MS Society, expresses the inherent value of quality rehabilitation trials for broadening clinical understandings of multiple sclerosis (MS) and bettering patient outcomes.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More